GO
Loading...

Enter multiple symbols separated by commas

AstraZeneca PLC

More

  • Best Move of the Year? Playing the Flu Tuesday, 29 Jan 2013 | 12:45 PM ET
    A man is given a flu shot by at the medical offices of Yaffe Ruden & Associates in New York.

    Amid all the bullishness about stocks this year, the swine flu play may be getting lost. Yes, one of the most effective strategies has been betting on shares of companies that benefit from the higher-than-expected flu cases.

  • Earnings Buzz: What to Watch in the Week Ahead Friday, 25 Jan 2013 | 4:41 PM ET

    Earnings season is shifting into high gear in the final week of January, with six Dow Jones components, and more than a fifth of the S&P 500 companies reporting.

  • Bye-Bye, Big Bonuses: Hello Claw-Backs and Caps Thursday, 3 Jan 2013 | 11:16 PM ET
    Big Banks Still Needed to Keep US Competitive: Bove

    Another nail in the coffin of pre-credit crisis bonus culture is set to come with the 2012-13 bonus season.

  • Europe Close Lower as Investors Lock in Profits Friday, 14 Dec 2012 | 11:36 AM ET

    European shares closed slightly lower on Friday as investors locked in profits ahead of the weekend and once again focused on the ongoing discussions surrounding the "fiscal cliff" in the U.S.

  • Early Movers: CLWR, S, BBY & More Thursday, 13 Dec 2012 | 7:54 AM ET

    Some of the names on the move ahead of the open.

  • Ever since James Watson and Francis Crick discovered the structure of DNA in 1953, scientists have been puzzling over how genes make us who we are.

  • AstraZeneca deepens collaboration with academia Wednesday, 31 Oct 2012 | 12:01 AM ET

    LONDON, Oct 31- British academic researchers have secured 7 million pounds of funding from the country's Medical Research Council to investigate a range of potential new drugs made available free-of-charge by AstraZeneca. AstraZeneca did initial tests on these chemicals but then put them on hold for a variety of reasons.

  • *AstraZeneca, Sanofi, Novartis all hit by patent loss in Q3. *Sanofi, Novartis forecast to post rises of 21 pct, 9 pct. While AstraZeneca faces years of continuing sales declines, due to a lack of new drugs to replace those losing protection, Sanofi and Novartis are turning the corner.

  • *Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. *Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.

  • *Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.

  • *Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.

  • Loss of exclusive drug dents AstraZeneca's Q3 Thursday, 25 Oct 2012 | 2:56 AM ET

    LONDON-- Anglo-Swedish pharmaceutical company AstraZeneca has reported a 56 percent drop in net income in the third quarter as it suffered from the loss of exclusivity on a big-selling drug. For the three months ending Sept. 30, AstraZeneca said Thursday that net profit fell to $1.5 billion compared to $3.5 billion a year earlier.

  • AstraZeneca, Ironwood partner on IBS drug in China Tuesday, 23 Oct 2012 | 11:58 AM ET

    British drug giant AstraZeneca PLC and a small U.S. drug developer, Ironwood Pharmaceuticals Inc., said Tuesday that they are teaming up to develop and then market Ironwood's new drug for irritable bowel syndrome in China.

  • Oct 12- Regulus Therapeutics Inc:. *Astrazeneca plc reports 18.3% passive stake in Regulus Therapeutics Inc. as of October 10- SEC filing.

  • *Jefferies cuts AstraZeneca PLC price target to 3,000 p from 3,100 p;. *Jefferies raises Bayer AG price target to 71 euros from 65 euros;. *Jefferies raises Eli Lilly price target to $36 from $35; rating.

  • Targacept announces a new round of job cuts Monday, 8 Oct 2012 | 11:58 AM ET

    WINSTON-SALEM, N.C.-- Targacept Inc. said Monday it will eliminate 26 jobs, or 38 percent of its staff positions, as it tries to cut more costs after its second significant drug failure of the year.

  • Oct 5- Fitch Ratings has affirmed Merck& Co.' s ratings as follows:. The ratings apply to approximately $21.5 billion in outstanding debt including the recent $2.5 billion debt issuance.

  • BRIEF-Colorpak Ltd updates on contract with Astrazeneca Wednesday, 3 Oct 2012 | 9:10 PM ET

    *Colorpak ltd- re-signing of Astrazeneca contract. *Colorpak- re-signs Astrazeneca Australia for $30 million supply contract with. extended contract term for a further 5 years.

  • RESEARCH ALERT-Panmure cuts Astrazeneca to hold Wednesday, 3 Oct 2012 | 3:54 AM ET

    *Panmure cuts Astrazeneca to hold from buy. For a summary of rating actions and price target changes on European companies:. Reuters Station users, click. 1580.

  • Shares in British pharmaceutical company AstraZeneca drop 1.5 percent, the biggest loser on the UK blue-chip FTSE 100, after the company suspends its share repurchase programme with immediate effect. AstraZeneca shares plummeted on the news, losing 3 percent in the first half an hour after the announcement to hit an intraday low before recovering.